EMA Validates Two Daiichi Sankyo EU Drug Applications
The EMA validated two marketing authorization applications for Daiichi Sankyo single-pill triple-combination lipid-lowering therapies for adults with hypercholesterolemia or mixed dyslipidemia.
Related stories
Colombia Government Presents Fiscal Reform Bill for 2027
The Colombian government presented a fiscal reform bill aimed at cutting spending and increasing revenue in 2027.
L impact | REGULATION | Oct 29, 2026, 10:52 PM UTC
Colombia Proposes Steep Spending Cut as Fiscal Woes Deepen
M impact | REGULATION | Oct 29, 2026, 10:52 PM UTC
Venezuela Names Oliver Blanco as New Foreign Minister
Delcy Rodríguez announced Oliver Blanco as Venezuela’s new foreign minister.
L impact | REGULATION | Oct 29, 2026, 10:34 PM UTC
Nasdaq to Delist Aldel Financial II After Listing Rule Breach
Nasdaq notified Aldel Financial II that its securities will be delisted after the company failed to comply with Listing Rule 5450(a)(2) and missed the deadline to submit a complian
M impact | REGULATION | Oct 29, 2026, 09:23 PM UTC
Nasdaq to Delist Glucotrack After Listing-Rule Exception Failure
Nasdaq notified Glucotrack on October 28 that its securities would be delisted after the closing bid price fell to $0.87 on October 14, failing the terms of an exception to Nasdaq
M impact | REGULATION | Oct 29, 2026, 09:05 PM UTC
Propanc Biopharma Receives Nasdaq Delisting Notice
Nasdaq said Propanc Biopharma failed to meet the $1.00 minimum bid price requirement and is ineligible for a standard compliance period following a recent reverse stock split.
M impact | REGULATION | Oct 29, 2026, 09:03 PM UTC